Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Anti-inflammatory agent 50 (compound a1), a derivative of Fusidic acid, exerts its effects through inhibition of inflammatory mediators including NO, IL-6, and TNF-α. It mitigates acute lung injury by modulating these mediators and suppressing the MAPK, NF-κB, and NLRP3 inflammasome signaling pathways [1]. |
In vitro | In LPS-stimulated RAW264.7 cells, Anti-inflammatory agent 50 (compound a1) inhibits inflammatory mediators including nitric oxide (NO) with an IC50 of 3.26 μM, interleukin-6 (IL-6) with an IC50 of 1.85 μM, and tumor necrosis factor-alpha (TNF-α) with an IC50 of 3.88 μM. Additionally, Anti-inflammatory agent 50 significantly suppresses the expression of certain immunorelated cytotoxic factors, such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) [1]. |
In vivo | Anti-inflammatory agent 50 (compound a1) mitigates pulmonary inflammation and decreases levels of NO, IL-6, TNF-α, COX-2, and iNOS in mice suffering from LPS-induced acute lung injury (ALI). It acts by attenuating the phosphorylation of p38 MAPK, c-JNK, and ERK, thereby inhibiting the mitogen-activated protein kinase (MAPK) signaling pathway. Furthermore, Anti-inflammatory agent 50 inhibits the activation of the NF-κB signaling pathway by preventing the phosphorylation of inhibitor of NF-κB alpha (IκBα) [1]. |
Molecular Weight | 673.88 |
Formula | C40H55N3O6 |
Cas No. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.